Device Trial Radar · NCT02674269
Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2")
Last checked: Nov 20, 2026Latest source record: Jun 16, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Oct 2016
Primary completion
Oct 2016
Study completion Oct 2016
Sponsor
- Lead sponsor
- UroGen Pharma Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Feb 4, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will investigate the safety and efficacy of UroGen's TC-3 Gel for sustained release of Botulinum Toxin A (BTX) in urinary bladder in patients with idiopathic overactive bladder.
Conditions
- Overactive Bladder
Interventions
300 IU of BotuGelTM (60ml)Drug
One intravesical instillation of 300 IU of botox in 60 ml of TC-3 gel
400 IU of BotuGelTM (60ml)Drug
One intravesical instillation of 400 IU of botox in 60 ml of TC-3 gel
TC-3 GelDevice
Intravesical instillation of 60 ml TC-3 gel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Urinary retentionTime frame: 6 weeks
3 more outcomes with a free account
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Rambam Health Care Campus
Haifa, Israel
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.